Clinical Oncology Next Generation Sequencing (NGS) is changing how cancer is diagnosed and treated by enabling clinicians to identify genetic mutations and select therapies tailored to individual patients. As precision oncology continues to advance, NGS is becoming increasingly important in improving diagnostic accuracy, treatment selection, and disease monitoring.

Despite its growing adoption, challenges such as testing costs, data interpretation, reimbursement, and access to advanced genomic technologies remain significant in many healthcare systems. At the same time, ongoing innovations in sequencing platforms and bioinformatics are making NGS more efficient and widely available.

What's your perspective?

Do you believe Clinical Oncology Next Generation Sequencing should become a standard part of cancer diagnosis for all eligible patients, or should its use remain limited to specific cancer types and clinical situations? Why?

👇 Share your thoughts and experiences in the comments. Let's discuss the opportunities, challenges, and future of precision oncology.